Johnson & Johnson Allegedly Concealed Elmiron Eye Damage
In a lawsuit filed against Johnson & Johnson on Friday, a Massachusetts man claims that he must now be examined for severe eye damage due to taking the medicine Elmiron to treat interstitial cystitis.
William Weber v. Johnson & Johnson
William Weber, the plaintiff, filed a lawsuit in federal court in New Jersey as part of consolidated litigation asserting that Johnson & Johnson and its affiliates hid the hazardous side effects of their bladder control medication from their consumers.
According to Weber, he took the medication between 2004 and 2019. He contends that the drug’s manufacturers were aware of the relationship between Elmiron and a high risk of severe damage to the retina, particularly the macula, and the resulting vision impairment associated with its usage. Weber alleges that neither he nor his doctors were warned, and as a consequence, he now has severe damage to his eyes.
The plaintiff argues that he is now substantially more likely to get Elmiron Maculopathy and requires medical and ophthalmological care to ensure the disease is detected early.
In 1996, Elmiron was approved by the Food and Drug Administration (FDA) under the generic name pentosan polysulfate sodium. The prescription medicine aids in the management of discomfort associated with interstitial cystitis, a condition that causes significant pain in the bladder and pelvic region, as well as an increase in urination frequency.
The medication works by thinning the blood. While Elmiron is the only oral medication approved by the FDA to treat interstitial cystitis specifically, the lawsuit emphasizes that it is not the sole therapy option for the ailment.
Weber alleges that Johnson & Johnson and its affiliates marketed Elmiron wrongfully. Despite the availability of other treatments, the lawsuit argues that the drug manufacturers falsely claimed Elmiron was the only oral medication available to treat interstitial cystitis.
Indeed, the lawsuit alleges that the FDA approved Elmiron based on incomplete testing of potential adverse effects, including eye damage. In addition, Weber cites multiple studies completed before FDA’s Elmiron approval that established a relation between the medicine and eyesight impairments.
Additionally, the lawsuit alleges that Johnson & Johnson continued to sell Elmiron despite accumulating evidence that the medicine causes severe eye damage.
Weber wishes to join the Elmiron MDL in order to represent individuals who were not warned about the drug’s potentially serious adverse effects.
Editor’s Note on Johnson & Johnson Elmiron Lawsuit:
The article is published to inform you of the recent lawsuit filed against Johnson & Johnson and its affiliates due to concealing the hazardous side effects of Elmiron.
Case Name & No.: William Weber v. Johnson & Johnson, Re: Elmiron Products Liability Litigation, MDL No. 2973
Jurisdiction: United States District Court, District of New Jersey
Products/Services: Bladder control medication Elmiron
Allegations: Johnson & Johnson and its affiliates marketed Elmiron wrongfully
Are you a user of Elmiron? Have you experienced vision loss or injury to your eyes? Tell us more by clicking the ”Contact Us’Us’ button. Let us hear your story.
Suggested Article: Johnson & Johnson’s OGX Shampoo Lawsuit 2021.